Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: A phase II trial

Investigational New Drugs

Volumn 28, Issue 1, 2010, Pages 83-90

  Lee, Keun Seok ^a   Ro, Jungsil ^a   Lee, Eun Sook ^a   Kang, Han Sung ^a   Kim, Seok Won ^a   Nam, Byung Ho ^a   Kwon, Youngmee ^a   Kim, Eun A ^a   Shin, Kyung Hwan ^a  

^a National Cancer Center   (South Korea)

Author keywords

Breast cancer; Gemcitabine; Paclitaxel; Pathologic complete response; Phase II

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; HORMONE RECEPTOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HOT FLUSH; HUMAN; LEUKOPENIA; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; STOMATITIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 74149089081     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9229-5     Document Type: Article

References (31)

1. B Fisher J Bryant N Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 1:CAS:528:DyaK1cXlsFCgurg%3D 9704717
2. HD Bear S Anderson RE Smith, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019 2027 10.1200/JCO.2005.04.1665 1:CAS:528:DC%2BD28Xlt1amur0%3D 16606972 (Pubitemid 46622110)
3. M Kaufmann GN Hortobagyi A Goldhirsch, et al. 2006 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 10.1200/JCO.2005.02.6187 16622270 (Pubitemid 46638994)
4. GF Schwartz GN Hortobagyi 2004 Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania Cancer 100 2512 2532 10.1002/cncr.20298 15197792 (Pubitemid 38715755)
5. MC Pinder Z Duan JS Goodwin, et al. 2007 Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 25 3808 3815 10.1200/JCO.2006.10.4976 1:CAS:528:DC%2BD2sXhtFanu7zI 17664460 (Pubitemid 47477254)
6. C Bernard-Marty M Mano M Paesmans, et al. 2003 Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients Ann Oncol 14 693 698 10.1093/annonc/mdg204 1:STN:280: DC%2BD3s7otlejtw%3D%3D 12702521 (Pubitemid 36621767)
7. SE Jones MA Savin FA Holmes, et al. 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 5381 5387 10.1200/JCO.2006.06.5391 1:CAS:528:DC%2BD2sXisVSjtQ%3D%3D 17135639 (Pubitemid 46623169)
8. KS Lee J Ro BH Nam, et al. 2008 A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer Breast Cancer Res Treat 109 481 489 10.1007/s10549-007-9672-y 1:CAS:528:DC%2BD1cXlvVCgtro%3D 17653851 (Pubitemid 351692059)
9. Slamon D, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. (abstr 52). Proceedings of the 29th Annual San Antonio Breast Cancer Symposium
10. JR Kroep G Giaccone C Tolis, et al. 2000 Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines Br J Cancer 83 1069 1076 10.1054/bjoc.2000.1399 1:CAS:528:DC%2BD3cXnsF2hsL4%3D 10993656
11. C Oliveras-Ferraros A Vazquez-Martin R Colomer, et al. 2008 Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling Int J Oncol 32 113 120 1:CAS:528:DC%2BD1cXhtVOlur0%3D 18097549
12. R Colomer A Llombart-Cussac A Lluch, et al. 2004 Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain Ann Oncol 15 201 206 10.1093/annonc/mdh048 1:STN:280:DC%2BD2c%2FlvVantg%3D%3D 14760109 (Pubitemid 38262615)
13. C Delfino G Caccia LR Gonzales, et al. 2004 Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer Oncology 66 18 23 10.1159/000076330 1:CAS:528:DC%2BD2cXitlyitL0%3D 15031594 (Pubitemid 38410675)
14. S Tomao A Romiti F Tomao, et al. 2006 A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer BMC Cancer 6 137 10.1186/1471-2407-6-137 16723016 (Pubitemid 44018119)
15. D Allouache SR Gawande M Tubiana-Hulin, et al. 2005 First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study BMC Cancer 5 151 10.1186/1471-2407-5-151 16316459 (Pubitemid 41800128)
16. M Demiray E Kurt T Evrensel, et al. 2005 Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure Cancer Invest 23 386 391 1:CAS:528:DC%2BD2MXhtFWjtrvF 16193637
17. KS Khoo SH Manzoor Zaidi V Srimuninnimit, et al. 2006 Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study Eur J Cancer 42 1797 1806 10.1016/j.ejca.2006.05.001 1:CAS:528:DC%2BD28XotFyltLc%3D 16846734 (Pubitemid 44149088)
18. P Vici E Capomolla P Foggi, et al. 2006 High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients J Exp Clin Cancer Res 25 39 44 1:CAS:528: DC%2BD28XkvVaktbY%3D 16761616
19. KS Albain SM Nag G Calderillo-Ruiz, et al. 2008 Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 3950 3957 10.1200/JCO.2007.11.9362 18711184
20. AD Seidman D Berry C Cirrincione, et al. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649 10.1200/JCO.2007.11. 6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D 18375893
21. JA Sparano M Wang S Martino, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D 18420499 (Pubitemid 351549913)
22. G Zornoza MJ Garcia-Velloso J Sola, et al. 2004 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer Eur J Surg Oncol 30 15 19 10.1016/j.ejso.2003.10.010 1:STN:280:DC%2BD2c%2Fjslaisw%3D%3D 14736517 (Pubitemid 38180986)
23. RL Wahl BA Siegel RE Coleman, et al. 2004 Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 277 285 10.1200/JCO.2004.04.148 14722036 (Pubitemid 41095092)
24. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
25. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 10.1016/0197-2456(89)90015-9 1:STN:280: DyaL1M7ps1SjsQ%3D%3D 2702835 (Pubitemid 19099520)
26. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
27. AU Buzdar SE Singletary RL Theriault, et al. 1999 Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer J Clin Oncol 17 3412 3417 1:CAS:528:DyaK1MXnvVGlt7w%3D 10550135
28. G von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
29. TR Evans A Yellowlees E Foster, et al. 2005 Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study J Clin Oncol 23 2988 2995 10.1200/JCO.2005.06.156 1:CAS:528:DC%2BD2MXkslGhu70%3D 15860854 (Pubitemid 46224118)
30. SB Kaye 1998 New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 Suppl 3 1 7 1:CAS:528:DyaK1cXlslWks7g%3D 9717984
31. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686